StockData
Virax Biolabs Group Ltd logo

Virax Biolabs Group Ltd (VRAX) stock

VRAXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends March 31
Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jul 6, 2026Score 9/30
$0.43−0.02 (-3.39%)

Close on Nov 18, 2026Market cap $249.06KP/E –Yield –

Virax Biolabs net income

Net income is the profit left for shareholders after every expense, interest and tax.

For fiscal 2026 it was -$5.02M. The highest annual figure on record is -$650.98K in fiscal 2021.

Annual net income

PeriodPeriod endValueChange
FY2026Mar 31, 2026-$5.02M–
FY2025Mar 31, 2025-$6.06M–
FY2024Mar 31, 2024-$6.73M–
FY2023Mar 31, 2023-$5.46M–
FY2022Mar 31, 2022-$1.71M–
FY2021Mar 31, 2021-$650.98K–

More Virax Biolabs figures

See a number that looks wrong?